HRTX241220P2500
- 1.35
- 0.000.00%
Heron Therapeutics Newsroom
Northland Securities Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $9
Heron Therapeutics (HRTX) Gets a Buy From Northland Securities
Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Institutional Investors Lost 28% Over the Past Week but Have Profited From Longer-term Gains
Benign Growth For Heron Therapeutics, Inc. (NASDAQ:HRTX) Underpins Stock's 30% Plummet
Heron Therapeutics Analyst Ratings
Heron Therapeutics Reports Q3 2024 Results and Narrows Guidance
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Needham Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Cuts Target Price to $4
Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript
Express News | Heron Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Sales Results and Narrowed Its FY24 Product Revenue Guidance
Express News | Adage Capital Management, L.p. Reports 5.84% Passive Stake in Heron Therapeutics as of Sept 30 - SEC Filing
Heron Therapeutics | 8-K: Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
Heron Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | Heron Therapeutics Narrows FY24 Guidance For Product Revenues, Net, Adjusted Operating Expenses, And Adjusted EBITDA
Heron Therapeutics GAAP EPS of -$0.03 In-line, Revenue of $32.81M Misses by $4.12M
Earnings Flash (HRTX) HERON THERAPEUTICS Reports Q3 Revenue $32.8M
Express News | Heron Therapeutics Outlook Q4 Net Revenue in Range of $37 Mln - $43 Mln
Express News | Heron Therapeutics Q3 Operating Expenses USD 27.81 Million
Express News | Heron Therapeutics Q3 Net Product Sales USD 32.81 Million